BioVie Inc. (BIVI)
NASDAQ: BIVI · Real-Time Price · USD
1.940
+0.160 (8.99%)
At close: Jun 26, 2026, 4:00 PM EDT
1.910
-0.030 (-1.55%)
After-hours: Jun 26, 2026, 7:33 PM EDT
BioVie Employees
BioVie had 13 employees as of June 30, 2025. The number of employees decreased by 1 or -7.14% compared to the previous year.
Employees
13
Change (1Y)
-1
Growth (1Y)
-7.14%
Revenue / Employee
n/a
Profits / Employee
-$1,535,386
Market Cap
14.63M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2025 | 13 | -1 | -7.14% | 13 | 0 |
| Jun 30, 2024 | 14 | -4 | -22.22% | 14 | 0 |
| Jun 30, 2023 | 18 | 5 | 38.46% | 18 | 0 |
| Jun 30, 2022 | 13 | 7 | 116.67% | 13 | 0 |
| Jun 30, 2021 | 6 | 2 | 50.00% | 6 | 0 |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BioLineRx | 24 |
| Passage Bio | 24 |
| Citius Pharmaceuticals | 23 |
| Jasper Therapeutics | 22 |
| BioCardia | 21 |
| IN8bio | 18 |
| Cocrystal Pharma | 10 |
| Lexaria Bioscience | 7 |
BIVI News
- 9 days ago - BioVie files $300M mixed securities shelf - TheFly
- 9 days ago - BioVie Registration statement: Registration filing - Filings
- 22 days ago - Did BioVie Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PRNewsWire
- 25 days ago - BioVie Transcript: Investor update - Transcripts
- 25 days ago - BioVie Slides: Corporate presentation - Filings
- 4 weeks ago - Join BioVie's Exclusive Live Investor Webinar and Q and A Session on June 2 - GlobeNewsWire
- 4 weeks ago - BioVie announces full enrollment of ADDRESS-LC trial of bezisterim - TheFly
- 4 weeks ago - BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID - GlobeNewsWire